Obesity – Page 9

Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment

8 months ago talkbio0Tagged Danuglipron, GLP-1 receptor, GLP-1/GIP therapies, Injury of liver, Metabolic Diseases, Obesity, Pfizer, Pharmaceutical competition, pipeline, Weight-Loss Agents

Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline

Novo Nordisk Invests $1.1 Billion to Expand GLP-1 Drug Manufacturing in Brazil

8 months ago talkbio0Tagged Brazil, Claros facility, Diabetes, Glucagon-Like Peptide 1, Investments, Montes, Nordisk, Obesity, Ozempic, pharmaceutical manufacturing, production, Wegovy

Novo Nordisk , GLP-1 production , Brazil investment , Wegovy and Ozempic , Diabetes treatment , Obesity treatment , Montes Claros facility , Pharmaceutical manufacturing

Drug pricing watchdog ICER offers ways to increase obesity drug access

8 months ago talkbio0Tagged Access, drug price, ICER, Obesity, Policy, Wegovy

ICER, Obesity, Access, Wegovy, Policy, drug price

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

9 months ago talkbio0Tagged lexicon, LX9851, Mechanism (attribute), Obesity

Obesity, LX9851, lexicon, Mechanism (attribute)

Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks

9 months ago talkbio0Tagged Gastric Inhibitory Polypeptide, glucagon, Glucagon-Like Peptide 1, Nordisk, Obesity, triple agonist, UBT251, United Laboratories International Holdings Limited

Novo Nordisk, UBT251, obesity treatment, triple agonist, weight loss, GLP-1, GIP, glucagon, The United Laboratories International Holdings Limited

GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space

9 months ago talkbio0Tagged Cell Differentiation process, competition, Glucagon-Like Peptide 1, Obesity, weight loss market

GLP-1 drugs, weight loss market, differentiation, competition, obesity treatment

Roche expands obesity pipeline, paying Zealand Pharma $1.65B upfront to codevelop amylin asset

9 months ago talkbio0Tagged competitive weight loss medication, drug pipeline, expansion, Obesity, Partnership, Roche 's

This deal represents a major expansion of Roche’s obesity drug pipeline and a significant partnership in the competitive weight loss medication market.

Viking Signs $150M Manufacturing Agreement with CordenPharma for Obesity Drug Candidate

9 months ago talkbio0Tagged CordenPharma, GLP-1/GIP, Manufacturing, Obesity, Viking, VK2735

Viking Therapeutics, CordenPharma, VK2735, obesity drug, manufacturing agreement, GLP-1/GIP dual agonist

Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735

9 months ago talkbio0Tagged alpha 1-antitrypsin, Capacity, Contract agreement, CordenPharma, Fill/finish, GLP-1/GIP Dual Agonist, Obesity, oral formulations, production, subcutaneous, Viking, VK2735

Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations

Harbour BioMed Launches Élancé Therapeutics to Develop Next-Generation Obesity Treatments

9 months ago talkbio0Tagged bispecific antibody technology, Élancé, Harbour BioMed, next-generation, Obesity

Harbour BioMed, Élancé Therapeutics, Obesity therapies, Bispecific antibody technology, Next-generation treatments